Use of Antibiotics to Enhance Treatment With Therapeutic Viruses

• US 20140271549A1
• Filed: 03/11/2014
• Published: 09/18/2014
• Est. Priority Date: 03/15/2013
• Status: Abandoned Application

• Current Assignee: Genelux Corporation
• Original Assignee: Genelux Corporation
• Inventors: Szalay, Aladar A.
• Application Number:
  US13/999,616
• Publication Number:
  US 20140271549A1
• Time in Patent Office: Days
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/431 containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
• CPC Class Codes: A61K 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 38/162 from virus
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C12N 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided are methods for increasing the therapeutic efficacy of viral therapy by administering an antibiotic effective against commensal bacteria with the viral therapy. Included are methods for treating cancers, tumors and metastases by administering the virus and the antibiotic.

Claims

1. A method for enhancing the effectiveness of a therapeutic virus, comprising administering an antibiotic with, before, after or during treatment with the therapeutic virus, to inhibit the growth of or kill commensal gut bacteria to thereby reduce the number of gut bacteria, wherein:

the antibiotic is an antibiotic that inhibits the growth of or kills commensal gut bacteria and is not an anti-cancer antibiotic; and

the antibiotic is administered in an amount that reduces or eliminates commensal gut bacteria.

2. The method of claim 1, wherein the therapeutic virus is administered to provide gene therapy and/or to treat cancers and tumors.

3. The method of claim 1, wherein the therapeutic virus is an oncolytic virus.

4. The method of claim 1, wherein the therapeutic virus is selected from among a retrovirus, adenovirus, lentivirus, herpes simplex virus, poxvirus and adeno-associated virus (AAV).

5. The method of claim 4, wherein the therapeutic virus is an oncolytic virus selected from among Newcastle Disease virus, parvovirus, vaccinia virus, measles virus, reovirus, oncolytic adenoviruses and vesicular stomatitis virus (VSV).

6. The method of claim 1, wherein the therapeutic virus is a vaccinia virus.

13. The method of claim 6, wherein the therapeutic virus is a Wyeth strain derived virus designated JX-294 or JX-594 or is an LIVP virus that is the virus designated GLV-1h68 and derivatives and modified forms thereof.

7. A method for treating cancers or tumors, comprising:

administering a therapeutic virus for treatment of cancers, tumors or metastases, wherein the therapeutic virus is effective for treating one or more of cancers, tumors or metastases; and

administering an antibiotic that is effective against commensal gut bacteria, wherein;

the antibiotic is administered before, after or with the therapeutic virus; and

the antibiotic is administered in an amount that reduces or eliminates commensal gut bacteria.

8. The method of claim 7, wherein the therapeutic virus is an oncolytic virus.

9. The method of claim 7, wherein the therapeutic virus is selected from among a retrovirus, adenovirus, lentivirus, herpes simplex virus, poxvirus and adeno-associated virus (AAV).

10. The method of claim 8, wherein the therapeutic virus is an oncolytic virus selected from among Newcastle Disease virus, parvovirus, a pox virus, measles virus, reovirus, vesicular stomatitis virus (VSV), oncolytic adenovirus, poliovirus and herpes simplex virus.

11. The method of claim 7, wherein the therapeutic virus is a vaccinia virus.

12. The method of claim 10, wherein the therapeutic virus is a pox virus that is a strain selected from among Western Reserve (WR), Copenhagen, Tashkent, Tian Tan, Lister, Wyeth, IHD-J, and IHD-W, Brighton, Ankara, MVA, Dairen I, LIPV, LC16M8, LC16MO, LIVP and WR 65-16 strains and modified forms of the strains.

14. The method of claim 11, wherein the vaccinia virus a Lister strain virus.

15. The method of claim 14, wherein the virus is an LIVP virus, a clonal strain of an LIVP virus, or a modified form thereof containing nucleic acid encoding a heterologous gene product.

16. The method of claim 15, wherein the nucleic acid encoding the heterologous gene product is inserted into or in place of a non-essential gene or region in the genome of the virus.

17. The method of claim 16, wherein the nucleic acid encoding the heterologous gene product is inserted at the hemagglutinin (HA), thymidine kinase TK), F14.5L, vaccinia growth factor (VGF), A35R, N1L, E2L/E3L, K1L/K2L, superoxide dismutase locus, 7.5K, C7-K1L, B13R+B14R, A26L or 14L gene loci in the genome of the virus.

18. The method of claim 15, wherein the virus is an LIVP virus or modified form thereof comprising a sequence of nucleotides set forth in SEQ ID NO:

2, or a sequence of nucleotides that has at least 95% sequence identity to SEQ ID NO;

2.

19. The method of claim 15, wherein the virus is a clonal strain of LIVP or a modified form thereof comprising a sequence of nucleotides selected from:

a) nucleotides 2,256-180,095 of SEQ ID NO;

3, nucleotides 11,243-182,721 of SEQ ID NO;

4, nucleotides 6,264-181,390 of SEQ ID NO;

5, nucleotides 7,044-181,820 of SEQ ID NO;

6, nucleotides 6,674-181,409 of SEQ ID NO;

7, nucleotides 6,716-181,367 of SEQ ID NO;

8 or nucleotides 6,899-181,870 of SEQ ID NO;

9;

b) a sequence of nucleotides that has at least 97% sequence identity to a sequence of nucleotides 2,256-180,095 of SEQ ID NO;

3, nucleotides 11,243-182,721 of SEQ ID NO;

4, nucleotides 6,264-181,390 of SEQ ID NO;

5, nucleotides 7,044-181,820 of SEQ ID NO;

6, nucleotides 6,674-181,409 of SEQ ID NO;

7, nucleotides 6,716-181,367 of SEQ ID NO;

8 or nucleotides 6,899-181,870 of SEQ ID NO;

9.

20. The method of claim 19, wherein the virus comprises a sequence of nucleotides set forth in any of SEQ ID NOS:

3-9, or a sequence of nucleotides that has at least 97% sequence identity to a sequence of nucleotides set forth in any of SEQ ID NOS;

3-9.

21. The method of claim 15, wherein the virus comprises heterologous nucleic acid that comprises a reporter gene or encodes a detectable gene product or a product that produces a detectable signal.

22. The method of claim 21, wherein the reporter gene encodes a fluorescent protein, a bioluminescent protein, a receptor or an enzyme.

23. The method of claim 22, wherein the encoded gene product is a fluorescent protein selected from among a green fluorescent protein, an enhanced green fluorescent protein, a blue fluorescent protein, a cyan fluorescent protein, a yellow fluorescent protein, a red fluorescent protein, or a far-red fluorescent protein.

24. The method of claim 15, wherein the virus encodes a product that is detectable or that induces a detectable signal.

25. The method of any of claim 15, wherein the virus comprises nucleic acid encoding a heterologous gene product that is a therapeutic agent a diagnostic agent or comprises a plurality thereof.

26. The method of claim 25, wherein the heterologous gene product is selected from among an anticancer agent, an antimetastatic agent, an antiangiogenic agent, an immunomodulatory molecule, an antigen, a cell matrix degradative gene, genes for tissue regeneration and reprogramming human somatic cells to pluripotency, enzymes that modify a substrate to produce a detectable product or signal or are detectable by antibodies, proteins that can bind a contrasting agent, genes for optical imaging or detection, genes for PET imaging and genes for MRI imaging.

27. The method of claim 15, wherein the virus comprises a sequence of nucleotides selected from among any of SEQ ID NOS:

1 and 10-19, or a sequence of nucleotides that exhibits at least 99% sequence identity to any of SEQ ID NOS;

1 and 10-19.

28. The method of claim 7, wherein the antibiotic is administered in an amount between about 1 mg and about 1000 mg.

29. The method of claim 7, wherein the antibiotic is administered prior to the administration of the virus.

30. The method of claim 29, wherein the antibiotic is administered at least, at about or at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 36 or 48 or more hours prior to the administration of the virus.

31. The method of claim 7, wherein the antibiotic is administered at the same time as the administration of the virus.

32. The method of claim 7, wherein the antibiotic is administered after the administration of the virus.

33. The method of claim 32, wherein the antibiotic is administered at least, at about or at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more hours, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or more days after the administration of the virus.

34. The method of claim 7, wherein the antibiotic is administered a plurality of times.

35. The method of claim 7, wherein the antibiotic is selected from among penicillins, penicillin combinations, tetracyclines, β

-lactam antibiotics, carbacephems, glycopeptides, aminoglycosides, ansamycins, macrolides, monobactams, nitrofurans, sulfonamides, lincosamides, lipopeptides, polypeptides, quinolones, drugs against mycobacteria, oxazolidinones, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, tazobactam, mupirocin, platensimycin, quinupristin/dalfopristin, thiamphenicol, tigecycline, tinidazole or trimethoprim and mixtures thereof.

36. The method of claim 7, wherein the antibiotic is selected from among penicillin, streptomycin, ampicillin, neomycin, metronidazole, vancomycin, tazobactam, meropenem, a mixture of penicillin and streptomycin, a mixture of ampicillin, neomycin, metronidazole and vancomycin, and a mixture of tazobactam, meropenem and vancomycin.

37. The method of claim 7, further comprising administering an antimycotic with the antibiotic or before or after the administration of the antibiotic or with the administration of the virus or before or after the administration of the virus, wherein the antimycotic is administered in an amount effective for treatment of any fungal infections.

38. A combination, comprising:

a first composition, comprising a therapeutic virus in a pharmaceutically acceptable vehicle, and

a second composition, comprising an antibiotic in a pharmaceutically acceptable vehicle, wherein the antibiotic inhibits the growth of or kills commensal gut bacteria to thereby reduce the number of gut bacteria and is not an anti-cancer antibiotic.

39. The combination of claim 38, wherein the therapeutic virus provides gene therapy and/or treats cancers and tumors.

40. The combination of claim 38, wherein the therapeutic virus is an oncolytic virus.

41. The combination of claim 38, wherein the therapeutic virus is a pox virus.

42. The combination of claim 41, wherein the therapeutic virus is a vaccinia virus.

43. The combination of claim 41, wherein the therapeutic virus is a pox virus that is a strain selected from among Western Reserve (WR), Copenhagen, Tashkent, Tian Tan, Lister, Wyeth, IHD-J, and IHD-W, Brighton, Ankara, MVA, Dairen I, LIPV, LC16M8, LC16MO, LIVP and WR 65-16 strains and modified forms of the strains.

44. The combination of claim 43, wherein the therapeutic virus is an LIVP strain virus.

45. The combination of claim 44, wherein the LIVP strain virus is the virus designated GLV-1h68 and derivatives and modified forms thereof.

46. The combination of claim 43, wherein the therapeutic virus is a Lister strain virus.

47. The combination of claim 38, wherein the antibiotic is selected from among penicillins, penicillin combinations, tetracyclines, β

-lactam antibiotics, carbacephems, glycopeptides, aminoglycosides, ansamycins, macrolides, monobactams, nitrofurans, sulfonamides, lincosamides, lipopeptides, polypeptides, quinolones, drugs against mycobacteria, oxazolidinones, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, tazobactam, mupirocin, platensimycin, quinupristin/dalfopristin, thiamphenicol, tigecycline, tinidazole or trimethoprim and mixtures thereof.